151 material Form 8-K filings that 136 companies we cover made with the SEC in February 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Erie Indemnity reported fourth-quarter 2023 net income of $110.9 million, or $2.12 per diluted share, up from $65.5 million, or $1.25, a year earlier. Full-year 2023 net income was $446.1 million, or $8.53 per diluted share, compared with $298.6 million, or $5.71, in 2022. The board also approved a quarterly Class A dividend of $1.275 per share, up from $1.190 a year earlier.
Q4 2023 total operating revenue was $817.7 million, up from $700.6 million in Q4 2022
Q4 2023 operating income rose 56.1% to $127.1 million, per the filing's highlights
Board approved Class A dividend of $1.275 per share, with a record date of April 9, 2024 and payable date of April 23, 2024
Results will be discussed in a pre-recorded webcast on February 27, 2024 at 10:00 a.m. ET
Berkshire Hathaway reported fourth-quarter 2023 net earnings attributable to shareholders of $37.6 billion, up from $18.1 billion a year earlier, and operating earnings of $8.5 billion, up from $6.6 billion. Investment and derivative gains of $29.1 billion made up most of the net earnings increase, and the company says investment gains in any quarter are usually not indicative of business performance. For the full year, net earnings were $96.2 billion compared with a loss of $22.8 billion in 2022.
Q4 2023 net earnings of $37.6 billion versus $18.1 billion in Q4 2022, including investment and derivative gains of $29.1 billion
Q4 2023 operating earnings of $8.5 billion versus $6.6 billion; insurance-underwriting earnings rose to $848 million from $160 million
Full-year 2023 net earnings of $96.2 billion versus a $22.8 billion loss in 2022; full-year operating earnings of $37.4 billion versus $30.9 billion
Berkshire repurchased about $2.2 billion of its shares in Q4 2023 and about $9.2 billion for the full year
Krystal Biotech reported fourth-quarter and full-year 2023 results, with net product revenue of $42.1 million in the quarter and $50.7 million for the year from VYJUVEK, which was approved in May 2023. The company posted net income of $8.7 million for the quarter versus a $32.1 million loss a year earlier, and $10.9 million for the year, which includes a $100.0 million gain from selling a Priority Review Voucher. The company also gave 2024 non-GAAP R&D and SG&A expense guidance of $150.0 million to $175.0 million.
Q4 2023 net product revenue was $42.1 million, versus no product revenue in Q4 2022.
Q4 2023 net income was $8.7 million ($0.31 per basic share), compared with a loss of $32.1 million in Q4 2022.
Full-year 2023 net income was $10.9 million, including a $100.0 million gain from the sale of a Priority Review Voucher.
2024 non-GAAP combined R&D and SG&A expense guidance is $150.0 million to $175.0 million; cash and investments were $594.1 million at December 31, 2023.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.